Harrington Discovery Institute focuses on advancing cures globally by supporting the development of new medicines in partnership with academic laboratories. The institute pairs scholars with project managers and advisors to facilitate the commercialization of therapeutic candidates.

Harrington Discovery Institute at University Hospitals

Harrington Discovery Institute

Harrington Discovery Institute at University Hospitals  | 695 followers on LinkedIn. Accelerating Breakthrough Discoveries Into Medicines | The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery &amp; Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. Harrington Discovery Institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.

Bronwyn Monroe

Advance Life Sciences Innovation | Venture Investments | BD | Strategy | Corporate Development

Shobha Parthasarathi

Sneha Natarajan

President, Chief Executive Officer, & CSO at Kurome Therapeutics, Inc.

Jan Rosenbaum

Lord Cameron, Chair of our Advisory Council, highlights on Sky News the Oxford-Harrington mission to accelerate therapeutics development for rare diseases, and the compelling motivations behind his involvement. See more here: https://lnkd.in/d8wsFYqb

Oxford-Harrington Rare Disease Centre

The Oxford-Harrington Rare Disease Centre announces the inaugural class of 2024 OHC Rare Disease Scholar Award Recipients, an exceptional group of scientists advancing groundbreaking treatments for rare and ultra-rare diseases. Chaired by former UK Prime Minister David Cameron, the OHC is committed to transforming lives with innovative therapies spanning rare neurological diseases, metabolic and developmental diseases, and childhood cancers. Each scholar will receive critical funding and industry support to accelerate their work toward clinical impact. Congratulations to the 2024 OHC Scholars!

Congratulations to the ten recipients of the 2024 Oxford-Harrington Rare Disease Scholars Award! This grant is awarded by the Oxford-Harrington Rare Disease Centre a partnership between the University of Oxford and Harrington Discovery Institute at University Hospitals and includes funding and personalized therapeutics development support to help advance new treatments into the clinic. Learn more: https://bit.ly/3YBwiWE #rarediseases University Hospitals

The Oxford-Harrington Rare Disease Centre Announces Inaugural 2024 Rare Disease Scholar Award Recipients 10 scientists have been selected for OHC’s first annual award to advance academic discoveries into clinical practice for rare diseases Jonathan S. Stamler, MD, President of Harrington Discovery Institute, University Hospitals added: “By supporting each OHC Scholar with funding and an experienced therapeutics development team, we are maximising the potential of their discoveries to advance into the clinic. We have seen success with this approach at Harrington Discovery Institute and we are excited about replicating the model at the OHC. I look forward to seeing the progress of these innovative initiatives and sharing their advancements as the OHC continues to work towards providing scalable solutions to address the rare disease challenge globally.”

Following the announcement of his role as Chair of our Advisory Council, Lord Cameron highlights in this video the Oxford-Harrington Rare Disease Centre as a brilliant collaboration between two great institutions: the University of Oxford and Harrington Discovery Institute at University Hospitals , translating science into medicines that make a difference. Read more: https://bit.ly/3NxM1zv

Former UK Prime Minister David Cameron Joins Oxford-Harrington Rare Disease Centre as Chair of our Advisory Council. As Chair of the Oxford-Harrington Rare Disease Centre Advisory Council, Lord Cameron will lead the international efforts of the OHC in its philanthropic mission, build partnerships, expertise and networks, while also focusing on extending global awareness of the OHC and its objectives. Lord Cameron said: “Of the causes I have advocated, this one really is very personal. Setting up Genomics England and establishing a world-leading database with hundreds of thousands of genomes is one of my proudest achievements as Prime Minister. Yet, to be truly transformational, genomics requires the best of academia, life sciences, pharmaceutical companies, philanthropy and venture capital from around the world to come together. That is what the Oxford-Harrington Rare Disease Centre sets out to do, convening those key players and uniting around a bold mission: to deliver 40 new treatments for rare diseases in the next decade. “As a father I know all too well the impact of rare diseases. We miss our son Ivan, who had a rare neurological disease, every day – all these years on our loss is still so raw. But the steps we are taking now means that, in the not-too-distant future, families like ours will have hope. It is vital that we try to give it to them.”

Press Release: Oxford-Harrington Rare Disease Centre Appoints Influential UK Leader in Health Innovation Policy, Baroness Nicola Blackwood, to its Advisory Council. The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford , UK and Harrington Discovery Institute at University Hospitals , Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, announces the appointment of Baroness Nicola Blackwood to the OHC Advisory Council. In her position on OHC’s Advisory Council, Baroness Blackwood will contribute to advancing OHC’s mission to drive life-changing discoveries in rare disease, with a particular focus on addressing critical unmet needs in the UK. Learn more: https://bit.ly/3MFNCD3

Seeking Innovators in Medicine Call for Nominations: Harrington Prize for Innovation in Medicine Do you know a physician-scientist whose work is transforming the field of medicine? Nominate them for the Harrington Prize, an award that celebrates outstanding innovation and clinical potential. Prize Highlights: · $20,000 honorarium · Lecture at the AAP-ASCI-APSA Joint Meeting · Participation in the Harrington Discovery Institute Scientific Symposium · Essay publication in the Journal of Clinical Investigation Eligibility Requirements: · Must hold an MD or MD/PhD · No age or citizenship restrictions · Self-nominations are not allowed Nomination Deadline: September 16, 2024. Learn more: https://bit.ly/4d2ZgD4 Let’s recognize those making groundbreaking strides in medicine! #HarringtonPrize #MedicalInnovation #ScientificAchievement

Today, we know more about the causes of diseases than ever before. Yet treatments and cures are lacking for more than 500 million people worldwide. According to the National Institutes of Health (NIH), 80 to 90% of research projects fail before reaching testing in humans. Pharmaceutical companies and venture capital investors are understandably discerning, favoring projects with proven results and replicability. The gap between promising scientific discoveries and new medicines has been widening for at least 20 years, during which funding for translational research – research that verifies therapeutic targets – has been dissipating. Strategic philanthropy can fill the gap by supporting efforts to achieve early-stage results where many projects tend to languish and lose attention because of investment risk. Philanthropy is playing a unique and critical role in supporting translational medicine aimed at advancing more candidates to drug development. Importantly, philanthropic institutions can encourage knowledge exchange and resource sharing between “siloed” academic, pharma industry, and healthcare institutions. The result of such collaboration builds the bridge to translate scientific breakthroughs into medical treatments that improve and save lives. Learn more: https://bit.ly/43UfPht

Researchers Identify Potential Therapeutic Target for Management of Thirst Disorders The cerebellum, often referred to as the ‘little brain’, has captivated researchers for centuries due to its unique structure and cellular complexity, as one of the most ancient brain regions in evolutionary terms. It has traditionally been viewed only as a motor control center; however, recent studies have revealed its involvement in non-motor functions such as cognition, emotion, memory, autonomic function, satiety and meal termination. In a recent mouse-model study, published in Nature Neuroscience, researchers at University Hospitals (UH), Harrington Discovery Institute at UH, and Case Western Reserve University have now found that the cerebellum also controls thirst, a major function necessary for survival. Specifically, the research team found that a hormone, asprosin, crosses from the periphery into the brain to activate Purkinje neurons in the cerebellum. This leads to an enhanced drive to seek and drink water. “Asprosin, a hormone our lab discovered in 2016, is known to stimulate food intake and maintain body weight by activating key ‘hunger’ neurons in a part of the brain called the hypothalamus, and works by binding a protein on the neuron surface called a ‘receptor,’” explained Atul Chopra, MD, PhD, senior author on the study, Investigator at Harrington Discovery Institute at UH and Associate Director of the Harrington Rare Disease Program, Attending Medical Geneticist at UH, and Associate Professor of Medicine, and Genetics and Genomics at Case Western Reserve School of Medicine. A receptor is necessary for a hormone to work, and in the case of asprosin’s ability to control appetite and body weight, that receptor is Ptprd. Besides the hypothalamus, the team found that it is also highly expressed in the cerebellum, although the functional significance of this was unknown. “At the outset, we wondered whether asprosin action in the cerebellum was to coordinate food intake with the hypothalamus, which turned out to be incorrect. The breakthrough came when Ila Mishra, a postdoctoral fellow in the lab, and now the head of her own lab at the University of Kentucky, discovered that mice generated to lack cerebellar responsiveness to asprosin exhibited reduced water intake. Our intended endpoint was measurement of food intake, not water intake, making this a serendipitous observation.” These mice also showed reduced Purkinje neuron activity accompanied by hypodipsia (reduced feelings of thirst). Their food intake, motor coordination, and learning remained unaffected. By contrast, mice generated to preclude hypothalamic responsiveness to asprosin show reduced food intake without impacting thirst. Read more: https://bit.ly/3zBiL7m

HARR

ORG:HARRINGTONDISCOVERY

Harrington Discovery Institute

name

homepage url

country

linkedin url

crunchbase url

sector

industry

monthly webtraffic

monthly webtraffic growth

invested in

Metrics